While working with mice, researchers identified an immune system cell that travels from the gut to the brain and attacks cells rather than protect them as it normally does.
It may seem counterintuitive, but health officials say that even after you get vaccinated against COVID-19, you still need to practice the usual pandemic
Share this article
Share this article
LOS ANGELES, Jan. 12, 2021 /PRNewswire/ Monarch Biosciences, Inc. (MonarchBio), a California-based life sciences company, announced today that it has recently received Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for the following U.S. patent applications:
No. 16/298,758 entitled Three-Dimensional Thin-Film Nitinol Devices (U.S. Patent 10,864,096)
No. 16/010,341 entitled Intrasaccular Thin-film Flow Diverters and Related Methods
No. 15/605,754 entitled Thin-Film Cuff for Endothelialization of Endovascular Grafts
No. 16/048,136 entitled Thin-Film Micromesh and Related Methods
Haynes and Boone LLP represented MonarchBio in the successful prosecution of these patent applications and other related applications.
The claims of the patent applications cover the manufacturing of three-dimensional thin-film nitinol (TFN) constructs and include TFN-based intrasaccular flow diverters, cuffs for endovascular
E-Mail
Scientists have determined the optimal conditions following a stem cell transplant that could control HIV without the need of an everyday pill, according to a study published today in
eLife.
Finding the right balance of stem cell dose, cell type and timing of antiretroviral therapy (ART) could potentially lead to a spontaneous cure of HIV.
There are only two cases of HIV cure to date: the Berlin Patient and the London Patient, who both received stem cell transplants with stem cells from donors that lack a molecule called CCR5, which HIV is attracted to. The major obstacle to HIV eradication is a latent reservoir of long-lived infected cells, and cure strategies aim to eliminate all infected cells or permanently prevent viral reactivation from latency, explains first author E. Fabian Cardozo-Ojeda, Senior Staff Scientist at the Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, US. We wanted to recreate the cures seen in the Ber
It takes time after vaccination for immunity to the virus to build up, and no vaccine is 100% effective. Plus, scientists don t yet know if the vaccine stops viral spread. Here s what s known so far.